Review



ampk activator 13  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress ampk activator 13
    SBEM induces PTX resistance in breast cancer cells by activating the AMPK pathway. (A) Flow cytometry analysis of apoptosis in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK <t>activator</t> <t>13</t> (5 µmol/l) for 24 h. (B) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the change in cell viability was determined by the CCK-8 assay. (C) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the relative expression levels of Bax, Bcl2, Caspase-3 and cleaved-Caspase-3 proteins were detected by western blotting. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; CCK-8, Cell Counting Kit-8; si, small interfering (RNA).
    Ampk Activator 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ampk+activator+13/AMPK+activator+13/pmc12572762-71-0-3
    Average 93 stars, based on 1 article reviews
    ampk activator 13 - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation"

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation

    Journal: Oncology Letters

    doi: 10.3892/ol.2025.15353

    SBEM induces PTX resistance in breast cancer cells by activating the AMPK pathway. (A) Flow cytometry analysis of apoptosis in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK activator 13 (5 µmol/l) for 24 h. (B) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the change in cell viability was determined by the CCK-8 assay. (C) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the relative expression levels of Bax, Bcl2, Caspase-3 and cleaved-Caspase-3 proteins were detected by western blotting. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; CCK-8, Cell Counting Kit-8; si, small interfering (RNA).
    Figure Legend Snippet: SBEM induces PTX resistance in breast cancer cells by activating the AMPK pathway. (A) Flow cytometry analysis of apoptosis in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK activator 13 (5 µmol/l) for 24 h. (B) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the change in cell viability was determined by the CCK-8 assay. (C) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the relative expression levels of Bax, Bcl2, Caspase-3 and cleaved-Caspase-3 proteins were detected by western blotting. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; CCK-8, Cell Counting Kit-8; si, small interfering (RNA).

    Techniques Used: Flow Cytometry, Transfection, CCK-8 Assay, Expressing, Western Blot, Cell Counting, Small Interfering RNA

    AMPK activator 13 restores drug sensitivity to PTX. Western blotting of DUSP16, p-DUSP16, MAPK, p-MAPK and SBEM protein levels in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK activator 13 for 24 h. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; DUSP16, dual specificity phosphatase 16; p-, phosphorylated; si, small interfering (RNA).
    Figure Legend Snippet: AMPK activator 13 restores drug sensitivity to PTX. Western blotting of DUSP16, p-DUSP16, MAPK, p-MAPK and SBEM protein levels in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK activator 13 for 24 h. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; DUSP16, dual specificity phosphatase 16; p-, phosphorylated; si, small interfering (RNA).

    Techniques Used: Western Blot, Transfection, Small Interfering RNA

    Related Articles

    Flow Cytometry:

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation
    Article Snippet: To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.. AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.. For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.

    Transfection:

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation
    Article Snippet: To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.. AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.. For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.

    CCK-8 Assay:

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation
    Article Snippet: To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.. AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.. For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.

    Expressing:

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation
    Article Snippet: To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.. AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.. For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.

    Western Blot:

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation
    Article Snippet: To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.. AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.. For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.

    Cell Counting:

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation
    Article Snippet: To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.. AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.. For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.

    Small Interfering RNA:

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation
    Article Snippet: To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.To evaluate whether SBEM overexpression induces PTX resistance, SKBR3 cells, which have relatively low SBEM expression, were divided into: SKBR3 (control), SKBR3/PTX + PTX, SKBR3 + PTX + Vector and SKBR3 + PTX + oeSBEM.. AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.. For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.For this, SUM190PT/PTX cells were divided into four groups: Control, AMPK activator 13, siSBEM and AMPK activator 13 + siSBEM.



    Similar Products

    ampk activator 13  (MedChemExpress)
    93
    MedChemExpress ampk activator 13
    SBEM induces PTX resistance in breast cancer cells by activating the AMPK pathway. (A) Flow cytometry analysis of apoptosis in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK <t>activator</t> <t>13</t> (5 µmol/l) for 24 h. (B) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the change in cell viability was determined by the CCK-8 assay. (C) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the relative expression levels of Bax, Bcl2, Caspase-3 and cleaved-Caspase-3 proteins were detected by western blotting. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; CCK-8, Cell Counting Kit-8; si, small interfering (RNA).
    Ampk Activator 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ampk+activator+13/AMPK+activator+13/pmc12572762-71-0-3
    Average 93 stars, based on 1 article reviews
    ampk activator 13 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    ampk activator  (MedChemExpress)
    93
    MedChemExpress ampk activator
    SBEM induces PTX resistance in breast cancer cells by activating the AMPK pathway. (A) Flow cytometry analysis of apoptosis in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK <t>activator</t> <t>13</t> (5 µmol/l) for 24 h. (B) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the change in cell viability was determined by the CCK-8 assay. (C) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the relative expression levels of Bax, Bcl2, Caspase-3 and cleaved-Caspase-3 proteins were detected by western blotting. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; CCK-8, Cell Counting Kit-8; si, small interfering (RNA).
    Ampk Activator, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ampk+activator+13/AMPK+activator+13/pm39603405-64-2-7
    Average 93 stars, based on 1 article reviews
    ampk activator - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    SBEM induces PTX resistance in breast cancer cells by activating the AMPK pathway. (A) Flow cytometry analysis of apoptosis in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK activator 13 (5 µmol/l) for 24 h. (B) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the change in cell viability was determined by the CCK-8 assay. (C) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the relative expression levels of Bax, Bcl2, Caspase-3 and cleaved-Caspase-3 proteins were detected by western blotting. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; CCK-8, Cell Counting Kit-8; si, small interfering (RNA).

    Journal: Oncology Letters

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation

    doi: 10.3892/ol.2025.15353

    Figure Lengend Snippet: SBEM induces PTX resistance in breast cancer cells by activating the AMPK pathway. (A) Flow cytometry analysis of apoptosis in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK activator 13 (5 µmol/l) for 24 h. (B) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the change in cell viability was determined by the CCK-8 assay. (C) The treatment of SUM190PT/PTX cells was the same as aforementioned. After the treatment, the relative expression levels of Bax, Bcl2, Caspase-3 and cleaved-Caspase-3 proteins were detected by western blotting. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; CCK-8, Cell Counting Kit-8; si, small interfering (RNA).

    Article Snippet: AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.

    Techniques: Flow Cytometry, Transfection, CCK-8 Assay, Expressing, Western Blot, Cell Counting, Small Interfering RNA

    AMPK activator 13 restores drug sensitivity to PTX. Western blotting of DUSP16, p-DUSP16, MAPK, p-MAPK and SBEM protein levels in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK activator 13 for 24 h. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; DUSP16, dual specificity phosphatase 16; p-, phosphorylated; si, small interfering (RNA).

    Journal: Oncology Letters

    Article Title: SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation

    doi: 10.3892/ol.2025.15353

    Figure Lengend Snippet: AMPK activator 13 restores drug sensitivity to PTX. Western blotting of DUSP16, p-DUSP16, MAPK, p-MAPK and SBEM protein levels in SUM190PT/PTX cells transfected with siRNA for 48 h and treated with AMPK activator 13 for 24 h. **P<0.01, ***P<0.001, ****P<0.0001. ns, not significant; PTX, paclitaxel; SBEM, small breast epithelial mucin; DUSP16, dual specificity phosphatase 16; p-, phosphorylated; si, small interfering (RNA).

    Article Snippet: AMPK activator 13 (MedChemExpress; cat. no. HY-155363), an AMPK signaling pathway activator , was used to investigate the role of SBEM in regulating AMPK signaling.

    Techniques: Western Blot, Transfection, Small Interfering RNA